Veramix

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Veramix

The medication designated as Veramix is a synthetic prescription-only hormonal agent. It is structurally similar to the natural steroid hormone progesterone and belongs to the class of drugs known as progestins or progestogens. The preparation acts by binding to and activating the progesterone receptors throughout the body, providing a predictable hormonal signal used to regulate various physiological processes.

Property Description
Active ingredient Medroxyprogesterone (often as MPA)
Form Oral tablet or Injectable aqueous suspension
Pharmacological class Progestin / Steroid Hormone
General Purpose Hormonal regulation and endometrial stabilization
Origin Synthetic derivative

What Type of Medicine is Veramix? (Identity and Classification)

Veramix is formally classified as a progestin, which is a specialized type of steroid hormone designed for therapeutic intervention. Its active ingredient is Medroxyprogesterone, most commonly used as the stable ester, Medroxyprogesterone acetate (MPA). This is a synthetic derivative of natural progesterone. The compound is widely recognized in medical practice for its efficacy in establishing sustained progestogenic effects.

Composition, Origin, and Available Forms

The medication is a single-ingredient product containing only the active compound, Medroxyprogesterone acetate. As a synthetic agent, it is prepared for administration via two primary routes: as an oral tablet for ingestion, and as a sterile injectable aqueous suspension for parenteral delivery. This versatility is a key differentiating factor, as it allows the medication to be used either for short-term modulation (oral tablet) or to provide a long-acting effect via the injectable formulation.

General Purpose of Progestin Hormonal Agents

The broad utility of this hormonal agent is centered on promoting hormonal regulation and stabilizing the reproductive endocrine system. By binding to the progesterone receptor, the drug functions to modulate the natural hormonal cycle. The general mechanism principles include stabilizing the lining of the uterus (endometrium) and inhibiting the pituitary's hormonal signals (antigonadotropic action) that drive ovulation. This ability to exert progestogenic activity is clinically recognized for its role in managing conditions that require cyclical hormonal support, such as regulating the menstrual cycle.

What side effects are possible with Veramix?

The official safety documentation for this medicine is based on comprehensive data from clinical trials and post-marketing surveillance, classified according to the incidence and the body system affected.

Adverse Reactions by Frequency and System-Organ Class

The most common adverse reactions documented in regulatory sources (classified as Very Common, or ge10% incidence) primarily involve the Gastrointestinal System and Blood/Lymphatic System. These typically include diarrhea, neutropenia (low white blood cell count), nausea, abdominal pain, fatigue, and decreased appetite. The occurrence of diarrhea and neutropenia is explicitly noted to be more frequent during the initial cycles of treatment.

Other frequently reported side effects (classified as Common) involve infections, headache, vomiting, and liver enzyme elevations (e.g., increased AST and ALT).

Serious Adverse Reactions and Safety Considerations

Regulatory agencies have highlighted several serious and clinically significant adverse reactions requiring mandated clinical management and monitoring:

  • Serious Hematologic Toxicity: This primarily involves neutropenia, which can lead to complications such as febrile neutropenia (fever with low white blood cells), an officially documented serious risk.
  • Venous Thromboembolism (VTE): Events such as deep vein thrombosis and pulmonary embolism are explicitly cited as documented risks.
  • Interstitial Lung Disease (ILD) / Pneumonitis: Severe and fatal cases have been officially reported, necessitating permanent discontinuation if Grade 3 or 4 toxicity occurs.
  • Hepatotoxicity: Significant increases in liver enzymes and bilirubin have been observed. Liver function tests must be monitored on a specific schedule (e.g., before treatment, every two weeks for the first two months, then monthly for the next two months).

Safety-related restrictions include the requirement for dose reduction or permanent discontinuation if certain Grade 3 or 4 toxicities (such as severe ILD/Pneumonitis or severe, persistent hepatotoxicity) are confirmed. Patients with severe hepatic impairment require a reduction in the officially recommended dose.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Veramix (Medroxyprogesterone) strictly defines the documented manifestations and the required emergency actions for an overdose. The clinical manifestations officially noted following excessive intake are typically non-severe, including nausea, vomiting, abdominal discomfort, fatigue, and headache. Hormonal symptoms such as breast tenderness, menstrual irregularities, and vaginal bleeding have also been reported in regulatory summaries.

Severity and Management

Official assessments state that high oral doses (up to 3 grams per day) have been officially documented as well tolerated, and the overdose is generally not likely to be life-threatening. No specific antidote is known or documented in the official labeling; therefore, the required management is strictly symptomatic and supportive treatment.

Immediate Actions Mandated by Regulators

Individuals must seek immediate medical attention and contact a Poison Control center for a suspected overdose. Urgent medical help, including calling emergency services, is strictly required only if life-threatening manifestations occur. This escalation is mandated if the affected person collapses, has a seizure, experiences trouble breathing, or cannot be awakened. Monitoring of vital signs may be part of the official emergency protocol.

Therapeutic Uses of Veramix

What Veramix Treats: Main Uses and Benefits

The therapeutic utility of Veramix (Medroxyprogesterone) is commonly used to provide targeted hormonal support in situations involving certain distressing symptoms and hormone-sensitive conditions. The medication contributes to easing the overall symptom load across several distinct clinical domains. Its uses span reproductive health to specialized supportive care.

The core indications involve the management of menstrual cycles and promoting predictability (addressing absent periods and abnormal uterine bleeding), managing chronic pain related to conditions like endometriosis, preventing unwanted growth of the uterine lining during estrogen therapy, and is considered relevant in contexts involving long-term management of fertility. It may be part of symptomatic management when appropriate in settings involving heightened systemic burden for palliative symptom support.

“It is commonly used to support patients during difficult episodes by easing distress and assisting with maintaining functional stability.”

Quick Fact: Relief for Systemic Imbalance

Veramix is commonly used when supportive symptom management is appropriate in situations involving systemic imbalance. It helps improve day-to-day comfort by promoting stability and predictability in conditions characterized by periods of heightened symptoms that may interfere with daily functioning.

Regulatory References

  1. Medroxyprogesterone - StatPearls - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

The official eligibility profile for the medicine referenced as Veramix, based on regulatory documentation for the similar product mebendazole (e.g., Vermox), specifies clear exclusions and conditional use rules.

Contraindicated Populations

Use of this medicine is strictly forbidden (contraindicated) for individuals who have a known hypersensitivity or allergic reaction to the active ingredient or any of the excipients. It is also contraindicated in pregnancy due to regulatory findings of potential risk to the fetus.

Age-Related and Conditional Use

Population Group Eligibility Status Regulatory Basis
Children under 1 year Not for Use Lack of sufficient safety data
Children 1–2 years Restricted Use Only if potential benefit outweighs risk
Children 2 years and older Allowed Safety and efficacy established
Breastfeeding Mothers Conditional Use Caution advised; use only if benefit outweighs risk to infant

Eligibility is also restricted for patients with certain hereditary problems such as fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency, who should not take this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Veramix (Medroxyprogesterone acetate/MPA) is primarily structured by its metabolic pathway, specifically interactions that alter the function of the cytochrome P450 3A4 enzyme (CYP3A4). These are officially classified as pharmacokinetic interactions that modify drug exposure, and all restrictions are based on documented outcomes found in government regulatory labeling.

Exposure-Altering Interactions

Co-administration with substances that induce the CYP3A4 enzyme increases the rate of Veramix's metabolic clearance. Potent inducers, such as Aminoglutethimide, Rifampicin, and certain anti-epileptic medicines like Carbamazepine, are listed in prescribing information as resulting in reduced Veramix plasma concentrations.

Conversely, inhibitors of the CYP3A4 pathway, including potent agents like Ketoconazole and Itraconazole, may decrease the metabolic clearance of Veramix, which can formally lead to increased systemic exposure.

Interactions with Herbal Products

Official documents note that the herbal product St. John’s Wort (Hypericum perforatum) is classified as an enzyme inducer. Co-administration is expected to reduce the overall progestogenic effect of Veramix by accelerating its clearance.

Regulatory documents do not list any absolute contraindications based solely on interaction risk, nor do they specify mandatory timing separation rules for the administration of oral Veramix and other medicines.

Mechanism of Action

Selective Inhibition of Calcium Channels

Veramix is a non-dihydropyridine calcium channel inhibitor that acts by blocking the L-type voltage-gated calcium channels (L-VGCCs) located in the membranes of both vascular smooth muscle cells and cardiac tissue. This action limits the flow of extracellular calcium ions ( Ca^2+) into these cells, reducing the availability of calcium required for excitation-contraction coupling and impulse propagation.


Modulation of Cardiac Electrical Activity

By altering calcium dynamics within the heart's conduction system, particularly the atrioventricular (AV) node, the drug slows the speed at which electrical impulses travel. This pathway effect prolongs the refractory period of the AV node, resulting in a decreased ventricular activation rate.


Reduction of Vascular Tone and Myocardial Contractility

The restriction of calcium influx causes vascular smooth muscle to relax (vasodilation), which reduces the systemic vascular resistance (SVR). Simultaneously, the compound induces a negative inotropic effect (decreased force of contraction), which lowers the myocardial oxygen consumption.

Dosage and Administration Information

How Veramix Is Used: Official Administration Guidelines

Veramix, which contains the progestin Medroxyprogesterone, is officially administered via two primary routes: as an oral tablet for ingestion or as a sterile aqueous suspension for parenteral delivery. The injectable suspension must never be administered intravenously (IV).

Oral Tablet Administration

Oral tablets are typically used in short-term, cyclical courses. For non-oncological conditions, the standardized oral dose is 5 mg or 10 mg of Medroxyprogesterone acetate (MPA) daily. This daily dose is generally taken for a period of 5 to 12 consecutive days per menstrual cycle, depending on the specific regimen. Tablets may be taken with or without food.

Injectable Administration

The injectable form provides a long-acting effect and is administered as a deep intramuscular (IM) injection (150 mg) or a subcutaneous (SC) injection (104 mg). Before administration, the suspension must be vigorously shaken to ensure the active ingredient is uniformly dispersed.

The IM injection is scheduled for administration once every three months (13 weeks), while the SC injection is scheduled every 12 to 14 weeks. Adherence to the prescribed interval is necessary for maintaining consistent therapeutic levels. Use of the injectable form for longer than two years is generally not recommended unless other options are deemed inadequate.

Administration Rules for Specific Populations

Oral use is not indicated prior to menarche. For post-partum mothers who are exclusively breast-feeding, the first injection is typically administered during or after the sixth week post-partum. If an oral dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Veramix

Evidence for Use in Hormonal and Menstrual Regulation

Research examined how Veramix was associated with changes in hormonal environment, and studies explored outcomes related to the frequency and intensity of abnormal uterine bleeding episodes and secondary amenorrhea (absent periods). Evidence for this application includes Randomized Controlled Trials (RCTs) that compared outcomes against placebo, and findings describe patterns observed in the studies, with outcomes observed over defined time intervals. Research describes the endometrial lining stabilization achieved when the agent was administered over defined time intervals. Long-term effects are not fully established, and follow-up durations were limited in many studies.

Research on Endometrial Stabilization and Hyperplasia Risk

Research explored the potential use of Veramix for endometrial stabilization in the context of preventing abnormal cell growth in postmenopausal women with an intact uterus receiving estrogen-only hormone therapy. Research examined the potential outcomes related to physiological strain, specifically tracking the incidence of abnormal cell growth, known as hyperplasia, over many years. Data show patterns related to the consistent finding of fewer cases of abnormal cell growth in the studied population compared to those receiving estrogen alone. The majority of high-quality evidence is derived from studies that used a specific class of estrogen.

Studies for Endometriosis-Associated Pain Management

Veramix was studied for its role in conditions involving periods of heightened symptoms, such as the pain associated with endometriosis. Research explored patient-reported outcomes describing perceived discomfort in women with surgically confirmed disease. Studies included RCTs and comparative trials where researchers monitored outcomes reflecting daily functioning, focusing on quantifying changes in menstrual and non-menstrual pelvic pain. The research follow-up duration was limited due to specific regulatory study protocols that required the monitoring of long-term physiological outcomes.

What Remains Uncertain About the Research Evidence

Authoritative scientific literature highlights several areas where the evidence is limited. Comparative evidence is often lacking in modern trials that directly assess Veramix against newer hormonal agents. Data for certain subgroups, such as those with specific comorbidities, remain insufficient. Furthermore, there is limited information for long-term outcomes concerning the patterns of symptom recurrence after treatment is fully stopped.

Frequently Asked Questions (FAQ)

Common questions about Veramix (FAQ)

Q: How is Veramix different from other medicines used for the same condition?

A: Veramix contains medroxyprogesterone acetate and is officially classified as a progestin, which is a type of synthetic steroid hormone. This specific classification and its mechanism of action—binding to progesterone receptors—define how it is distinct from other classes of medicines that may be used to treat similar conditions.


Q: Can Veramix be taken for a long time?

A: Official guidance notes that use of the injectable form for longer than two years is generally not recommended unless other treatment options are deemed inadequate. This is due to the officially noted potential for a decrease in bone mineral density. The oral tablet regimens are typically prescribed for cyclical, short-term courses.


Q: How long does it typically take for Veramix to start working?

A: The oral tablet form is known to be rapidly absorbed, reaching its highest concentration in the blood within a few hours after ingestion. However, the time required to achieve a noticeable therapeutic effect varies depending on the medical condition being treated and the specific hormonal regimen prescribed.


Q: What happens if a dose of Veramix is missed?

A: For the oral tablet, regulatory guidance states that a missed dose should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. Missing a scheduled injection, especially if outside the recommended interval, is a situation that is generally managed by consulting a healthcare professional.


Q: Can older adults safely use Veramix?

A: While specific studies on the geriatric population are limited, official guidance suggests that consideration is given to age-related factors. This is because elderly patients may be more likely to have certain conditions that need to be reviewed.


Q: What is the typical duration of treatment with Veramix?

A: The official documentation describes various treatment durations depending on the form and condition addressed. Oral tablets are often used in short-term cycles (e.g., 5 to 12 consecutive days per menstrual cycle). The injectable form is given every 12 to 13 weeks, with long-term use generally not exceeding two years.


Q: Do studies show Veramix is more effective than placebo?

A: Regulatory reviews of research evidence have shown that Veramix provided an observed benefit in the studied populations. For example, when used with estrogen in postmenopausal women, studies demonstrated patterns associated with fewer cases of abnormal cell growth in the uterus when compared to those receiving estrogen alone.


Q: Why is Veramix sometimes taken in combination with another drug?

A: Official labeling indicates that Veramix is used in combination with estrogen-only hormone therapy. This is specifically done in postmenopausal women who still have a uterus to help reduce the officially documented risk of abnormal cell growth in the uterine lining.


Q: Is Veramix taken with food or on an empty stomach?

A: Official product information states that the oral tablet form of Veramix may be taken with or without food. While food can slightly increase the amount of active medicine absorbed, this difference is not considered clinically significant for its intended use.


Q: Does Veramix cause weight gain, according to patient reports?

A: Yes, official documentation lists weight gain as a documented adverse reaction reported in clinical data. Some regulatory sources also note that progestogens can potentially cause fluid retention, which may contribute to weight changes.


Q: Do many people experience a rash while taking Veramix?

A: Rash is listed in official documents as a possible undesirable effect. Other documented skin reactions include acne, hives, and hair loss, though the frequency of these effects varies.


Q: Is Veramix safe to use during pregnancy or while breastfeeding?

A: Veramix is contraindicated, or strictly forbidden, during pregnancy due to regulatory findings of potential risk to the developing fetus. For breastfeeding mothers, it is used only when the healthcare provider determines that the potential benefits are greater than the potential risks to the infant.


Q: Can Veramix affect my ability to drive or operate machinery?

A: Official warnings note that Veramix may cause side effects such as dizziness, sleepiness, or somnolence. Official documents suggest that individuals using Veramix should be aware that these effects may impact their ability to perform tasks requiring alertness.


Q: Does Veramix interact with common over-the-counter pain relievers?

A: Official product information specifically lists interactions with medicines that alter the CYP3A4 enzyme, such as certain anti-epileptic drugs and the herbal product St. John's Wort. There is no explicit general warning or listed interaction for common over-the-counter pain relievers.


Q: Can I stop taking Veramix as soon as my symptoms improve?

A: The official label specifies a strict dosing regimen, such as a fixed number of days for the oral tablet or fixed intervals for the injection. Official product information focuses on following the prescribed regimen as written, rather than adjusting based solely on immediate symptom improvement.


Q: Does Veramix have a generic version available?

A: Yes, regulatory and supply notices confirm that generic versions of the drug containing medroxyprogesterone acetate are available in many regions.


Q: Is Veramix known to cause stomach upset?

A: Official documentation lists several common gastrointestinal adverse reactions, including diarrhea, nausea, and abdominal pain. These effects are often grouped together by users as a general 'stomach upset' and are noted to occur more frequently in the initial stages of treatment.


Q: Does Veramix affect blood sugar levels?

A: Yes, official documentation states that patients receiving Veramix may exhibit decreased glucose tolerance. Official documents indicate that diabetic patients are typically monitored while using this medicine.


Q: What should be discussed with a doctor before starting Veramix?

A: The official label suggests a pre-treatment discussion that typically covers any prior history of blood clots (thromboembolic disorders), breast cancer, liver impairment, and factors affecting bone or blood sugar health. This ensures the healthcare provider has all necessary information.


Q: Can Veramix cause mood changes?

A: Yes, regulatory documents list several psychiatric effects, such as depression, anxiety, insomnia, and irritability as common or very common undesirable effects. Official documentation lists psychiatric effects, suggesting awareness of this potential is important.


Q: What are the exclusion criteria for clinical trials of Veramix?

A: Official trial protocols and regulatory reviews note that individuals with a history of certain severe conditions were typically excluded from participation. These conditions often included a history of severe cardiovascular events, certain types of cancer, unexplained vaginal bleeding, or certain severe liver conditions.

How should Veramix be stored and disposed of?

Storage and Protection Requirements

Veramix (medroxyprogesterone) must be stored strictly according to the conditions detailed in the regulatory label to maintain stability and effectiveness.

  • Temperature: Store at Controlled Room Temperature (CRT), defined as 20^circ to 25 C (68^circ to 77 F). The product must be protected from freezing and excessive heat.
  • Container: Keep the medication in the original container, tightly closed, and protect it from moisture and direct light. Injectable vials must remain in the carton for light protection.
  • Child Safety: It is a mandatory regulatory requirement to keep Veramix out of the sight and reach of children and store it locked up.

Official Disposal Rules

Disposal must strictly adhere to regulatory guidelines to avoid environmental contamination.

  • Method: Unused or expired medication must be disposed of in accordance with all local and national regulations. Patients should consult a healthcare professional for specific disposal instructions.
  • Environmental Protection: The label requires that disposal avoids release to the environment and explicitly prohibits flushing the product into surface water or the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Veramix found in:

A-Z Index: